B
SNDX icon

Braidwell’s Syndax Pharmaceuticals SNDX Stock Holding History

Braidwell’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-920,049
Closed -$19.4M – 90
2023
Q1 		$19.4M Sell
920,049
-322,753
-26% -$8.03M 0.64% 53
2022
Q4 		$31.6M Buy
+1,242,802
New +$29M 1.06% 37

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Braidwell's SNDX Position: Q2 2023 in Review

Braidwell sold out of Syndax Pharmaceuticals (SNDX) in Q2 2023, closing a stake of 920,049 shares — an estimated $19.4M sold.

Braidwell first reported a position in SNDX in Q4 2022 and held it in 2 quarters. The position peaked at $31.6M in Q4 2022. 166 funds tracked by Wall St. Rank hold SNDX as of Q2 2023.

  • Braidwell reported no remaining Syndax Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Braidwell sold 920,049 Syndax Pharmaceuticals shares in Q2 2023, an estimated $19.4M.
  • Braidwell first reported a position in Syndax Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Braidwell's Syndax Pharmaceuticals position peaked at $31.6M in Q4 2022.
  • 166 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2023.

Based on Braidwell's 13F filing for Q2 2023, filed 14 Aug 2023.